ライフサイエンスコーパス: norfloxacin

1 m for enoxacin, 700 nm for ciprofloxacin and norfloxacin).

2 ifloxacin-to-sarafloxacin, and pefloxacin-to-norfloxacin.

3 the DNA gyrase inhibitors coumermycin A1 and norfloxacin.

4 ce and does not survive on medium containing norfloxacin.

5 presence of a 1 mM concentration gradient of norfloxacin.

6 resistance to two major antibacterial drugs--norfloxacin, a fluoroquinolone, and erythromycin, a macr

7 In this work, we demonstrate that norfloxacin, a model quinolone, converts Escherichia col

8 Furthermore, we showed that portions of norfloxacin accumulated by starved cells were pumped out

9 in the accumulation of lipophilic molecules (norfloxacin and chenodeoxycholate) and a small increase

10 less rapid influx of two lipophilic agents, norfloxacin and chenodeoxycholate.

11 Norfloxacin and ciprofloxacin - d8 were used as internal

12 s well as a fourfold increase in the MICs of norfloxacin and ciprofloxacin for these two strains.

13 scripts and a 2-fold decrease in the MICs of norfloxacin and ciprofloxacin in strain RN6390.

14 gococci to the same compounds, as well as to norfloxacin and ciprofloxacin.

15 aphenyl phosphonium and the fluoroquinolones norfloxacin and ciprofloxacin.

16 NA cleavage was also seen in the presence of norfloxacin and oxolinic acid, two quinolones that are i

17 nt showed a 2-fold increase in resistance to norfloxacin and rhodamine, both substrates of the NorC t

18 r levofloxacin, 2.00 (95% CI, 1.06-3.79) for norfloxacin, and 1.17 (95% CI, .59-2.31) for ofloxacin.

19 ased resistance toward H(2)O(2), vancomycin, norfloxacin, and ciprofloxacin under anaerobic condition

20 ations of gentamicin, tobramycin, ofloxacin, norfloxacin, and ciprofloxacin.

21 ktonic cells more susceptible to tobramycin, norfloxacin, and hydrogen peroxide.

22 The drugs are propranolol, simvastatin, norfloxacin, and warfarin, which in combination would co

23 well as between psorospermin and A-62176 and norfloxacin, are consistent with this model and provide

24 on of seven fluoroquinolones (marbofloxacin, norfloxacin as internal standard, ciprofloxacin, danoflo

25 ger than caliper readings for ciprofloxacin, norfloxacin, aztreonam, erythromycin, clindamycin, and t

26 ty to quinolones and to amphipathic cations (norfloxacin, benzalkonium chloride, cetrimide, pentamidi

27 drug-DNA-enzyme complexes, we show: (i) that norfloxacin binding to DNA induces a structural alterati

28 Norfloxacin blocked decatenation in wild-type strains, b

29 ase IV and gyrase, with potencies similar to norfloxacin but 10-fold lower than newer agents, for exa

30 cumulation level of a hydrophilic quinolone, norfloxacin, by M. smegmatis harboring a plasmid carryin

31 Instead, norfloxacin causes DNA damage, as evidenced by the induc

32 tocleavage reactions of the fluoroquinolones norfloxacin, ciprofloxacin, and enoxacin.

33 Here, we show that the FQ drugs norfloxacin, ciprofloxacin, and enrofloxacin are powerfu

34 spiked with nine quinolones (marbofloxacin, norfloxacin, ciprofloxacin, danofloxacin, enrofloxacin,

35 neral inhibition of DNA helicases by Topo IV-norfloxacin-DNA ternary complexes did not require the cl

36 ess the effect of topoisomerase IV (Topo IV)-norfloxacin-DNA ternary complexes on the DnaB, T7 gene 4

37 Norfloxacin efflux mediated by LfrA was competed for str

38 s taking fluoroquinolone antibiotics such as norfloxacin exhibit a low incidence of convulsions and a

39 umulation of the fluoroquinolone antibiotic, norfloxacin, in proteoliposomes.

40 Quinolone drugs, such as norfloxacin, inhibit the type 2 topoisomerases, DNA gyra

41 t concentration (0.003 mg/ml), ofloxacin and norfloxacin inhibited keratocyte proliferation significa

42 Norfloxacin inhibition of Topo IV induces a slow decline

43 ylactoid reactions induced by ciprofloxacin, norfloxacin, lomefloxacin, moxifloxacin, and baicalin.

44 We estimate a flux of about 10 norfloxacin molecules per second per OmpF trimer in the

45 in fish farming waters is presented, having Norfloxacin (NFX) as target compound.

46 electrode is prepared and applied to detect norfloxacin (NFX) based on its electrochemical reduction

47 We show (i) that Gyr-norfloxacin (Norf)-DNA and Topo IV-Norf-DNA, but not Gyr

48 sarafloxacin (SRFX, IC(50), 0.96 mug L(-1)), norfloxacin (NRFX, IC(50), 0.78 mug L(-1)), ofloxacin (O

49 Furthermore, ciprofloxacin, norfloxacin, ofloxacin, and gatifloxacin exhibited conce

50 Commonly used antibiotics (sulfamethazine, norfloxacin, ofloxacin, tetracycline, and erythromycin)

51 prevent secondary bacterial infection, 0.3% norfloxacin or 0.25 % chloramphenicol were prescribed.

52 l-designed study supported the use of either norfloxacin or amoxicillin-clavulanic acid in the treatm

53 At pH 5, where norfloxacin permeability across pure phospholipid membra

54 fection (hazard ratio [HR], 4.43), long-term norfloxacin prophylaxis (HR, 2.69), recent infection by

55 Norfloxacin prophylaxis resulted in savings between $221

56 e phthalate ester hydrolase, a fragment of a norfloxacin resistance-like transporter, and the convers

57 and 620 nm for enoxacin, ciprofloxacin, and norfloxacin, respectively).

58 responding to two different charge states of norfloxacin that bacteria are likely to encounter in the

59 us to inhibit selectively with the quinolone norfloxacin topo IV, gyrase, both enzymes, or neither en

60 nion activity is required for formation of a norfloxacin-topoisomerase IV-DNA ternary complex that ca

61 have increased sensitivity to low levels of norfloxacin treatment, but the mutations had more pronou

62 topoisomerase IV, or both, were resistant to norfloxacin, we determined that specific interactions be

63 ndac, ibuprofen, ketoprofen, diclofenac, and norfloxacin) were infused into rats with biliary fistula

64 ics, namely ciprofloxacin, sarafloxacin, and norfloxacin, were found to be equally or more potent tha

65 Modification of norfloxacin yields molecules such as compound 4 that pot